Abstract 1501P
Background
The Gender differences in the clinical symptoms presentation (CSP) are known and already studied in many settings of medicine, such as Cardiology and Neurology. However, these differences have been studied less deeply in Oncology and Palliative Care. Our analysis focused on evluating how gender can affect the CSP in an integrated outpatient clinic between Radiotherapy and Palliative Care (RaP).
Methods
This is a monocentric, observational study carried out in the RaP integrated outpatient clinic in a Research Cancer Hospital (IRCCS, IRST - Meldola, Italy). Descriptive statistics were reported for each Edmonton Symptom Assessment System (ESAS) item, separately by gender. Additionally, a set of linear models were developed to predict ESAS items score. Multivariable linear model incorporated all other symptoms, clinical characteristics (e.g tumor location), and the sex variable to evaluate possible gender effects. All analyses were performed using R statistical software.
Results
212 patients were enrolled in the study between 2016 and 2020. Most of the symptoms showed significant gender differences. Specifically, the symptom "Pain” showed higer values in the male population (mean: M5.1 vs. F 4.4). Conversely, the symptom "Anxiety” showed higer values in the female population (mean. M 2.0 vs F 3.0). Finally, the "total symptom distress score” resulted in higer values in the female population (mean: M 23.0 vs F 25.4). Interestingly, the symptom "malaise” is the only that showed an almost perfect equity for all values (mean M1.9 vs F 2.0). The linear model aimed at assessing, ceteris paribus, report 0.9 additional points than females (p= 0.053). Conversely, keeping constant all other factors, females report 0.95 higer expression of anxiety (p=0.002).
Conclusions
The gender differences in the CSP and their distribution highligheted in our analysis are important in the new subfield of medicine called "Gender Medicine". Especially in palliative care, data relating to patients symptoms is necessary to reach the goal of the best supoportive care. Additional studeis will be necessary to improve our knowledge in this field.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
L. Tontini.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1574P - Medical oncology residents mentors (MORM): A target for resiliency interventions
Presenter: David Paez
Session: Poster session 10
1575P - Smoke-free policies in outdoor areas: A potential cancer prevention strategy in Spain
Presenter: Karen Ramírez Cervantes
Session: Poster session 10
1576P - Smoking and lung cancer mortality in Italian men and women: 2003-2019
Presenter: Diego Serraino
Session: Poster session 10
1577P - Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study
Presenter: Marta Garcia De Herreros
Session: Poster session 10
1578P - Perception of LMIC oncologists on meaningful cancer trial endpoints and value of cancer drugs
Presenter: Soumitra Shankar Datta
Session: Poster session 10
1579P - The Dutch national adolescent and young adult (AYA) cancer care network, a data driven learning healthcare system
Presenter: Winette Van Der Graaf
Session: Poster session 10
1580P - Impact of social determinants of health (SDOH) on disparities in next-generation sequencing (NGS) testing in cancer patients (pts) in the US
Presenter: Chadi Hage Chehade
Session: Poster session 10
1581P - AI enabled intervention increased real-world guideline compliant care: Improving genomic testing and cascade genetics for women with ovarian cancer (OC)
Presenter: Premal Thaker
Session: Poster session 10
1582P - Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD)
Presenter: Lorena Incorvaia
Session: Poster session 10
1583P - Trial-level surrogacy of intermediate endpoints in adjuvant or neoadjuvant use of immune checkpoint blockade
Presenter: Luís Leite
Session: Poster session 10